The Community Resource in Targeted Therapies
Driving Knowledge. Empowering Change. Optimizing Outcomes.
ONCAlert | Upfront Therapy for mRCC

COMBI-AD and BRIM8 Studies in Melanoma

Michael A. Postow, MD
Published Online: 10:53 PM, Fri October 20, 2017


Michael A. Postow, MD, medical oncologist, Memorial Sloan Kettering Cancer Center, discusses BRAF and MEK inhibitor combinations studies in melanoma.
 

Copyright © TargetedOnc 2018 Intellisphere, LLC. All Rights Reserved.